REGULATORY

• Japan Approves Moderna and AstraZeneca COVID-19 Vaccines
  May 21, 2021

• AstraZeneca, Moderna COVID-19 Vaccines in Line for Japan Approval on May 21
  May 21, 2021

• Give AstraZeneca Shots to People Who Want, Regardless of Priority Order: Lawmakers
  May 21, 2021

• Japan Govt Eyes Expedited Approval Process to Push Homegrown Vaccines
  May 20, 2021

• LDP Panels Submit Proposal to PM for Commercialization of Japan-Made Vaccines
  May 19, 2021

• LDP Study Group’s Draft Proposal Urges Price Maintenance for Patented Drugs
  May 19, 2021

• Pharma to Govt: Maintain Prices of Patented Drugs, It’s the Global Standard
  May 18, 2021

• MHLW Proposes Lifting Domestic Ban on Cannabis-Derived Drugs, Seeking “Ingredient-Based” Regulation
  May 18, 2021

• Japan’s 1st Sakigake-Designated Oncolytic Virus Up for Advisory Panel Review on May 24
  May 18, 2021

• AstraZeneca, Moderna COVID-19 Vaccines Up for Key Panel Review on May 20
  May 17, 2021

• Japan, Pfizer Agree on 50 Million Extra Vaccine Doses by Sept-End
  May 17, 2021

• Eisai’s EZH2 Inhibitor Up for PAFSC Review on May 28
  May 17, 2021

• Daiichi Sankyo CEO Urges Rethink of Vaccine Approval System
  May 17, 2021

• LDP Project Team Urges Overhaul of Unpredictable Pricing System: Proposal
  May 14, 2021

• LDP Panels Call for Emergency Approval Process, Eyes Japan Made Vaccines
  May 14, 2021

• No Serious Safety Concerns Detected for Comirnaty: MHLW Safety Panels
  May 14, 2021

• 1st Oral SMA Med Risdiplam Up for PAFSC Review on May 26
  May 14, 2021

• Pharma Groups Want Price Maintenance for Patented Meds, Payer Sees It “Natural” to Rectify Gap: Chuikyo
  May 13, 2021

• Chuikyo OKs Re-Pricing for Tecentriq, Vyndaqel; 3 I/O Peers Challenge Cuts in Vain
  May 13, 2021

• Operating Profit Rate for Cost-Based Method Updated to 15.5%: Chuikyo
  May 13, 2021

ページ

• « 先頭
• ‹ Prev
• …
• 147
• 148
• 149
• 150
• 151
• 152
• 153
• 154
• 155
• …
• Next ›
• 最終 »